TY - JOUR
T1 - Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma
T2 - From the LWP-EBMT, Eurocord, and CIBMTR
AU - Fatobene, Giancarlo
AU - Rocha, Vanderson
AU - St. Martin, Andrew
AU - Hamadani, Mehdi
AU - Robinson, Stephen
AU - Bashey, Asad
AU - Boumendil, Ariane
AU - Brunstein, Claudio
AU - Castagna, Luca
AU - Dominietto, Alida
AU - Finel, Hervé
AU - Chalandon, Yves
AU - Kenzey, Chantal
AU - Kharfan-Dabaja, Mohamed
AU - Labussière-Wallet, Hélène
AU - Moraleda, Jose M.
AU - Pastano, Rocco
AU - Perales, Miguel Angel
AU - El Ayoubi, Hanadi Rafii
AU - Ruggeri, Annalisa
AU - Sureda, Anna
AU - Volt, Fernanda
AU - Yakoub-Agha, Ibrahim
AU - Zhang, Mei Jie
AU - Gluckman, Eliane
AU - Montoto, Silvia
AU - Eapen, Mary
N1 - Publisher Copyright:
© 2020 by American Society of Clinical Oncology
PY - 2020
Y1 - 2020
N2 - PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing non-myeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P, .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively). CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.
AB - PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing non-myeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P, .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively). CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.
UR - http://www.scopus.com/inward/record.url?scp=85084380128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084380128&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.02408
DO - 10.1200/JCO.19.02408
M3 - Article
C2 - 32031876
AN - SCOPUS:85084380128
SN - 0732-183X
VL - 38
SP - 1518
EP - 1526
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 14
ER -
